Patents Assigned to Pharmacyclics, Inc.
  • PURINONE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20140378446
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 30, 2013
    Publication date: December 25, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Yan Shunqi, Longcheng Wang, Leah Lynn Frye
  • TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY
    Publication number: 20140371241
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Application
    Filed: March 5, 2014
    Publication date: December 18, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. BUGGY, Tarak D. Mody, Richard B. Love, John C. Byrd, Betty Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy Jo Johnson
  • Selective inhibitors of histone deacetylase
    Patent number: 8906954
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: December 9, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Erik Verner, Sriram Balasubramanian, Joseph J. Buggy
  • Indole derivatives as inhibitors of histone deacetylase
    Patent number: 8900565
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF
    Publication number: 20140341989
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: September 13, 2011
    Publication date: November 20, 2014
    Applicants: PHARMACYCLICS, INC.
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
    Patent number: 8883199
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
    Patent number: 8883803
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: November 11, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph Buggy, David Loury, Wei Chen
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8883435
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 11, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140275125
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 22, 2013
    Publication date: September 18, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140243355
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 13, 2013
    Publication date: August 28, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8809273
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 19, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • FACTOR VIIA INHIBITOR
    Publication number: 20140221667
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. DICKMAN, Dange Vijay KUMAR, Colin O'BRYAN, Roopa RAI, William Dvorak SHRADER
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140212485
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • Hydroxamates as therapeutic agents
    Patent number: 8779171
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: July 15, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
  • 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
    Patent number: 8778625
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 15, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20140194446
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 10, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Jospeh J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140187564
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 3, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140187565
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 14, 2013
    Publication date: July 3, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8759516
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: June 24, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140171453
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 19, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN